Sec. 241. MEDICAL COUNTERMEASURES AGAINST BIOWARFARE THREATS

493 words·~2 min read·/statute-compilations/comps-10665/sec-241

A research copy — for the controlling text, always check the official state or federal source. Not legal advice.

## SEC. 241 MEDICAL COUNTERMEASURES AGAINST BIOWARFARE THREATS ###

(a)Funding Of the amounts appropriated pursuant to section 201 for fiscal year 1993, not more than $59,670,000 shall be available for the medical component of the Biological Defense Research Program

(BDRP)of the Department of Defense. ###

(b)Limitations ####

(1)Funds appropriated or otherwise made available for the Department of Defense for fiscal year 1993 may be obligated and expended for product development, and for research, development, testing, and evaluation, of medical countermeasures against biowarfare threat agents only in accordance with this section. ####

(2)Of the funds made available pursuant to subsection (a), not more than $10,000,000 may be obligated or expended for research, development, test, or evaluation of medical countermeasures against far-term validated biowarfare threat agents. ####

(3)Of the funds made available pursuant to subsection

(a)other than funds made available pursuant to paragraph

(2)for the purpose set out in that paragraph— #####

(A)not more than 80 percent may be obligated and expended for product development, or for research, development, test, or evaluation, of medical countermeasures against near-term validated biowarfare threat agents; and #####

(B)not more than 20 percent may be obligated or expended for product development, or for research, development, test, or evaluation, of medical countermeasures against mid-term validated biowarfare threat agents. ###

(c)Definitions In this section: ####

(1)The term “**validated biowarfare threat agent**” means a biological agent that— #####

(A)is named in the biological warfare threat list published by the Defense Intelligence Agency; and #####

(B)is identified as a biowarfare threat by the Deputy Chief of Staff of the Army for Intelligence in accordance with Army regulations applicable to intelligence support for the medical component of the Biological Defense Research Program. ####

(2)The term “**near-term validated biowarfare threat agent**” means a validated biowarfare threat agent that has been, or is being, developed or produced for weaponization within 5 years, as assessed and determined by the Defense Intelligence Agency. ####

(3)The term “**mid-term validated biowarfare threat agent**” means a validated biowarfare threat agent that is an emerging biowarfare threat, is the object of research by a foreign threat country, and will be ready for weaponization in more than 5 years and less than 10 years, as assessed and determined by the Defense Intelligence Agency. ####

(4)The term “**far-term validated biowarfare threat agent**” means a validated biowarfare threat agent that is a future biowarfare threat, is the object of research by a foreign threat country, and could be ready for weaponization in more than 10 years and less than 20 years, as assessed and determined by the Defense Intelligence Agency. ####

(5)The term “**weaponization**” means incorporation into usable ordnance or other militarily useful means of delivery. * * * * * * * # TITLE III OPERATION AND MAINTENANCE * * * * * * * ## subtitle C Environmental Provisions * * * * * * *